The book covers the latest breakthroughs in nanotechnology applied to cancer research. It examines how biomarkers and ligands are transforming preclinical cancer research by enabling the development of precision nanomedicines, targeted therapeutic strategies, and innovative drug delivery systems. Overall, by bridging multiple disciplines and providing a comprehensive overview of current advances and emerging trends, it equips readers with the knowledge to accelerate translational cancer research and the development of novel anticancer therapeutics.The chapters delve into key concepts such as the design and synthesis of ligand-functionalized nanoparticles, the role of biomarkers in cancer prognosis, and the integration of nanotechnology in personalized medicine. Expert contributors provide insights into the use of nanoparticles for imaging and drug delivery, highlighting the potential of nanotechnology to enhance therapeutic efficacy while minimizing side effects.The book is targeted towards oncologists, cancer researchers, medical students, pharmaceutical scientists, and healthcare professionals involved in cancer research and drug development. It serves as a valuable reference for research, fosters interdisciplinary collaboration, and provides an important resource for students and early-career researchers working in cancer nanotechnology and translational oncology.

The book covers the latest breakthroughs in nanotechnology applied to cancer research. It examines how biomarkers and ligands are transforming preclinical cancer research by enabling the development of precision nanomedicines, targeted therapeutic strategies, and innovative drug delivery systems. Overall, by bridging multiple disciplines and providing a comprehensive overview of current advances and emerging trends, it equips readers with the knowledge to accelerate translational cancer research and the development of novel anticancer therapeutics.The chapters delve into key concepts such as the design and synthesis of ligand-functionalized nanoparticles, the role of biomarkers in cancer prognosis, and the integration of nanotechnology in personalized medicine. Expert contributors provide insights into the use of nanoparticles for imaging and drug delivery, highlighting the potential of nanotechnology to enhance therapeutic efficacy while minimizing side effects.The book is targeted towards oncologists, cancer researchers, medical students, pharmaceutical scientists, and healthcare professionals involved in cancer research and drug development. It serves as a valuable reference for research, fosters interdisciplinary collaboration, and provides an important resource for students and early-career researchers working in cancer nanotechnology and translational oncology.

The book covers the latest breakthroughs in nanotechnology applied to cancer research. It examines how biomarkers and ligands are transforming preclinical cancer research by enabling the development of precision nanomedicines, targeted therapeutic strategies, and innovative drug delivery systems. Overall, by bridging multiple disciplines and providing a comprehensive overview of current advances and emerging trends, it equips readers with the knowledge to accelerate translational cancer research and the development of novel anticancer therapeutics.The chapters delve into key concepts such as the design and synthesis of ligand-functionalized nanoparticles, the role of biomarkers in cancer prognosis, and the integration of nanotechnology in personalized medicine. Expert contributors provide insights into the use of nanoparticles for imaging and drug delivery, highlighting the potential of nanotechnology to enhance therapeutic efficacy while minimizing side effects.The book is targeted towards oncologists, cancer researchers, medical students, pharmaceutical scientists, and healthcare professionals involved in cancer research and drug development. It serves as a valuable reference for research, fosters interdisciplinary collaboration, and provides an important resource for students and early-career researchers working in cancer nanotechnology and translational oncology.